Clinical Trials Logo

Filter by:
NCT ID: NCT05883579 Recruiting - Clinical trials for Chronic Total Occlusion of Coronary Artery

Application of Coronary Artery Chronic Total Occlusion Scoring Systems

CTO-PCI
Start date: April 1, 2023
Phase:
Study type: Observational

Studying the prediction ability of different CTO scoring systems on Asian CTO PCI population with their relation to technical success and developing a newer stepwise approach depending on these CTO scoring systems for choosing the suggested successful approach considering collateral channel assessment.

NCT ID: NCT05883969 Recruiting - Cerebral Palsy Clinical Trials

GO-PLAY - Early Family-Centered Intervention for Infants With High-Risk of Cerebral Palsy

GO-PLAY
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Background. Early diagnosis of cerebral palsy (CP) is important to enable appropriate intervention at a time when neuroplasticity is at its highest. Early intervention with focus on family-centered, home-based, parent-involved, and supervised by specialist therapists show positive cognitive and motor outcomes. This study adhere to international guidelines for early diagnosis and intervention, and include community therapists to ensure regular follow-up during and after the intervention period. The aim of the current study is to compare the effectiveness of an early intervention program added to standard care, relative to standard care alone, on the early motor development in children from both a newborn and infant detectable risk pathway in a Danish multi-site setting. Methods. In a randomized, controlled trial the response to the GO-PLAY (Goal Oriented ParentaL supported home ActivitY) intervention program added to standard care is superior to standard care alone is evaluated. The investigators will include infants from the Cerebral Palsy - Early Diagnosis and Intervention Trial (CP-EDIT registered separately at ClinicalTrials) and collect data at baseline, after intervention and at follow up when the children are 2 years corrected age. The hypotheses are that the GO-PLAY intervention is more effective than standard care when the children are re-evaluated at the end of 6 months of intervention and that the parents involved in the GO-PLAY intervention will exhibit less signs of stress and anxiety and perceive the services that they are receiving as family-centered to a greater extent than parents of children receiving standard care. Discussion. Approximately half of all infants with high risk of CP display high risk indicators identifiable by early screening before 5 months of age described as the newborn detectable risk pathway. The other half of all infants with CP are detected by parents, caregivers or health care professionals when displaying delayed motor milestones (e.g. hand asymmetry or not sitting at 9 months) and described as infant detectable risk pathway. There is a need to investigate if early intervention is effective in all infants with high suspicion of CP, also the ones with unremarkable neonatal history. Further, a systematic early intervention has not been tested in infants at high risk of CP in Denmark, where public health services include physiotherapy free of charge for infants with CP.

NCT ID: NCT05885386 Recruiting - Pheochromocytoma Clinical Trials

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL). Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent. Inthisstudy,temozolomidewill be used preoperatively in order to change unresectable tumors to resectable and reduce the high risk of surgery.

NCT ID: NCT05885399 Recruiting - Clinical trials for Paraganglioma, Malignant

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Penpulimab is specifically an immune check-point inhibitor of PD1 and has been approved for the treatment of several malignancies.This phase II trial studies the efficacy and safety of penpulimab in the treatment of MPP patients who fail to other systemic therapy.

NCT ID: NCT05886101 Recruiting - Clinical trials for Work-Related Condition

Increase Health Literacy Through Health Education to Improve Menstruation Related Self-care and Work Productivity

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The aim of the study is to increase health literacy, especially in menstruation self-care, and empower female RMG workers through health education by an occupational nurse, and as a consequent improve work productivity in RMG factories in Dhaka, Bangladesh

NCT ID: NCT05888545 Recruiting - Clinical trials for Intrauterine Adhesion

Clinical Study on a Novel Anti-adhesion Barrier Film

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The aim of this clinical study was to verify the effectiveness and safety of the anti-adhesion diaphragm in preventing intrauterine adhesions.

NCT ID: NCT05891912 Recruiting - Clinical trials for Older Adults Institutionalized in Residential Homes

Active Aging With Technological Devices

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Clinical trial with users of health care centres and nursing homes in Extremadura (Spain). Inclusion criteria are: women and men over 55 years of age with a Minimental State Examination (MMSE) equal or higher than 21 (no cognitive impairment or mild to moderate cognitive impairment) who are able to walk independently. Exclusion criteria are: patients with severe cognitive impairment or language impairment that prevents the use of verbal communication, non-autonomous gait and severe limitation of mobility at the level of the upper limb. Treatment schedule: 30 min sessions, twice a week during 12 weeks - 1 session per week: 15min small TABLET and 15min LIGHTS game. - 1 session per week: 15min TABLE TABLET and 15min game of grape harvesting. The intervention will be carried out by occupational therapists or physiotherapists. The intervention period and evaluations will be performed as follows: - Training of Occupational therapists/physiotherapists: 1 week prior to the start of the intervention for. - Week 0- Initial measurements - Week 1-12: device interventions - Week 13: Final measurements - Week 17: First follow-up measurement - Week 21: Second follow-up measurement

NCT ID: NCT05893472 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.

Start date: April 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of the combination of venetoclax and HAA regimen in young, newly diagnosed acute myeloid leukemia patients under the age of 60.

NCT ID: NCT05897346 Recruiting - Smoking Cessation Clinical Trials

Training Secondary School Students as Anti-smoke Ambassadors Using the Service-learning Model

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Building the community's capacity by training youngsters to refer smokers to professional smoking cessation services offers a good strategy to support smoking cessation. Peer pressure is considered the most common reason for smoking in young people. Smoking cessation interventions that target peers are likely to have substantial effects. This health promotion project based on the service-learning model will provide opportunity for young people to learn and practice the AWARD model with hands-on experience under the supervision of nursing students who are considered experienced peer counselors.

NCT ID: NCT05900466 Recruiting - Clinical trials for Fibromyalgia Syndrome

Metformin for Fibromyalgia Symptoms (INFORM Trial)

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of the project is to evaluate the safety and efficacy of low dose metformin for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose metformin conditions will show greater improvement in FMS symptoms than those who are in the placebo group. Further, the investigators hypothesize that metformin will increase phosphorylated AMPK in peripheral immune cells of FMS patients and will decrease the transcription of mTORC1, NLRP3 inflammasome, and nociceptive cytokines interleukin 1beta and interleukin 18.